Adaptive Biotechnologies and NeoGenomics: A Powerful Partnership for Blood Cancer Patients

Adaptive Biotechnologies (ADPT) and NeoGenomics (NEO) have joined forces in a multi-year exclusive strategic commercial collaboration to advance minimal residual disease (MRD) monitoring options for patients with select blood cancers. This partnership combines Adaptive's FDA-cleared clonoSEQ test with NeoGenomics' COMPASS and CHART assessment services, creating a comprehensive and personalized diagnostic solution for blood cancer patients.



The integration of clonoSEQ with COMPASS and CHART services enables clinicians to obtain real-time insights into disease progression and treatment effectiveness, which can lead to improved patient outcomes. By simultaneously identifying patient-specific DNA sequences at initial diagnosis, the partnership eliminates potential delays in MRD monitoring setup. Additionally, the seamless longitudinal monitoring of disease burden through CHART assessments allows clinicians to leverage MRD results at the most medically appropriate timepoints, even if they are less familiar with MRD testing.

The collaboration between Adaptive and NeoGenomics is expected to significantly impact their market share in the blood cancer diagnostics sector. By combining Adaptive's FDA-cleared clonoSEQ test with NeoGenomics' extensive network and market presence in oncology testing services, both companies will be able to capture a larger share of the growing $2.5 billion global MRD testing market. This partnership will drive increased test volumes for both Adaptive and NeoGenomics, further solidifying their market positions in the blood cancer diagnostics sector.

Moreover, the partnership could accelerate clinical trial recruitment, as many trials now require clonoSEQ MRD testing. The collaboration creates a pre-qualified patient pool for these trials, potentially speeding up drug development in blood cancers. This could give Adaptive and NeoGenomics an edge in the market by being associated with innovative therapies.

In conclusion, the partnership between Adaptive Biotechnologies and NeoGenomics is a significant development in the blood cancer diagnostics sector. By combining their complementary capabilities, the companies are poised to enhance patient care, expand market reach, and strengthen their respective portfolios. This collaboration has the potential to transform the landscape of blood cancer diagnostics and improve patient outcomes.